AI Summary
✦ ClarthaValuation Metrics
Trading 16.4% above historical median. Valuation is stable — currently in the strongly overvalued zone (z-score: +1.37). Confidence: 88%.
Live forward EPS implies next-12-month EPS of ₹17.50. Applying the stock's normalized valuation corridor produces a fair range of ₹271.95 to ₹333.38, with base value near ₹304.50 (+23.8% vs current price).
Live forward estimate anchored to the company's historical valuation corridor.
Forward EPS
₹17.50
Forward P/E
14.1x
Base Fair Value
₹304.50
Fair Range
₹271.95 - ₹333.38
Upside To Base
+23.8%
Estimate Source
Live forward EPS
Growth Estimate
-9.9%
5Y Average
15.92
Current
20.26
Overvalued
19.05
Undervalued
15.54
5Y Average
6.46
Current
8.22
Overvalued
7.24
Undervalued
5.70
5Y Average
1.30
Current
1.65
Overvalued
1.49
Undervalued
1.10
Peers & Comparison
Sector: Materials · Theme: Packaging
| Company | Rev. Growth | Margin | P/E | vs Avg | 52W Perf. |
|---|---|---|---|---|---|
POLY MEDICURE LIMITED POLYMEDPackaging | +38.6% | 15.8% | 60.1x Fair | 0% vs avg | +1.0% |
EPL LIMITED trades at a discount (20.1x vs peer avg 60.1x), suggesting potential undervaluation relative to the Packaging cohort. Peers include POLY MEDICURE LIMITED — selected based on business model, industry classification, market cap similarity, and business theme alignment.
Financials
Real statement data for revenue, earnings quality, conversion, and balance-sheet coverage. Monetary values are shown in Rs crore.
Latest revenue
₹353 CrMar 2026Latest net profit
₹43 CrMar 2026Latest EPS
₹1.34Mar 2026Net margin
17.0%Mar 2026Performance
Bars show revenue and net profit. The line shows net margin.
- Revenue
- Net income
- Net margin %
Earnings
Revenue is shown in crores. EPS is rupees per share.
- Revenue
- EPS
Revenue to profit conversion
Bridge from operating numbers to profit for the latest reported period.
Latest reported period: Mar 2026
Debt level and coverage
Debt, cash and free cash flow compared on the same crore scale.
- Debt
- Free cash flow
- Cash & equivalents
Results
| Metric | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 297 | 304 | 340 | 322 | 314 | 330 | 358 | 319 | 317 | 334 | 349 | 347 | 353 |
| Expenses + | 236 | 244 | 273 | 258 | 259 | 271 | 294 | 264 | 258 | 272 | 283 | 282 | 293 |
| Operating Profit | 61 | 60 | 68 | 64 | 56 | 59 | 64 | 54 | 59 | 62 | 66 | 64 | 60 |
| OPM % | 21% | 20% | 20% | 20% | 18% | 18% | 18% | 17% | 19% | 19% | 19% | 19% | 17% |
| Other Income + | 25 | 2 | 19 | 14 | 44 | 20 | 47 | 30 | 29 | 8 | 79 | 90 | 14 |
| Interest | 6 | 5 | 5 | 6 | 6 | 5 | 6 | 7 | 6 | 6 | 7 | 10 | 10 |
| Depreciation | 33 | 31 | 30 | 30 | 28 | 27 | 27 | 28 | 28 | 29 | 30 | 30 | 33 |
| Profit before tax | 47 | 26 | 52 | 42 | 65 | 47 | 78 | 49 | 54 | 34 | 108 | 115 | 31 |
| Tax % | -24% | -7% | 20% | -19% | 11% | 18% | 18% | 11% | -18% | 8% | 13% | -10% | -40% |
| Net Profit + | 59 | 27 | 41 | 50 | 58 | 39 | 64 | 44 | 64 | 32 | 94 | 126 | 43 |
| EPS in Rs | 1.84 | 0.86 | 1.29 | 1.56 | 1.82 | 1.21 | 1.99 | 1.38 | 1.99 | 0.99 | 2.94 | 3.95 | 1.34 |
| Raw PDF |
All values in ₹ Crores unless otherwise stated. Source: Screener Master (Standalone).
Events Timeline
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Board Meeting Intimation for Considering The Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter Ended On June 30, 2026.
Issuance And Allotment Of Commercial Papers Amounting To Rs. 60 Crore Of EPL Limited